Podcast Episodes
Back to Search
Episode 69: Testis Cancer Christmas Special: 2020 year in review
Season 1 Episode 69
Christian Kollmannsberger gets into the Christmas spirit by discussing highlights of 2020.
5 years, 10 months ago
Episode 68: Uromigos Paper of the Month - a molecular classification of renal cancer in Cancer Cell
Season 1 Episode 68
Kim Rathmell discusses this paper, which divides clear cell renal cancer into seven relevant subgroups. Brian askes an interesting question at one po…
5 years, 10 months ago
Episode 67: The Third Uromigos Debate - PD1/VEGF vs PD1/CTLA4 for front line renal cancer
Season 1 Episode 67
David McDermott and Brian Rini debate treatment options in front line renal cancer. It's hard to identify any winners from this podcast.
5 years, 11 months ago
Episode 66: Uromigos Paper of the Month - Two papers in Nature Medicine on neoadjuvant immune combinations in bladder cancer
Season 1 Episode 66
Pam Sharma and Michiel Van Der Heijden discuss neoadjuvant PD(L)1 + CTLA4 inhibition in urothelial cancer.
5 years, 11 months ago
Episode 65: Review of the International Kidney Cancer Symposium
Season 1 Episode 65
Gretchen Vaughan, Kidney Cancer Association CEO, discusses the upcoming International Kidney Cancer Symposium meeting and KCA's grant program. Tom an…
5 years, 11 months ago
Episode 64: The Second Uromigos debate with Nobel Laureate Bill Kaelin on new biomarker vs new drugs in RCC
Season 1 Episode 64
'New Drugs vs New Biomarkers' Bill Kaelin (Nobel Laureate) vs Tom Powles (keen cyclist), extend their discussion from KCRS20 in the 2nd Uromigos Deba…
5 years, 11 months ago
Episode 63: The First Uromigos Debate: front line immune therapy vs maintenance avelumab in bladder cancer
Season 1 Episode 63
Dr. Peter O'Donnell and Prof. Tom Powles debate front line treatment options in urothelial cancer.
6 years ago
Episode 62: James Eastham's Uromigos Paper of the Month - Prostatectomy +/- Neoadjuvant Chemo
Season 1 Episode 62
A large randomised investigator-initiated Alliance study gives insight in to perioperative treatments for high risk prostate cancer.
6 years ago
Episode 61: Nick James discusses the latest update of the STAMPEDE study
Season 1 Episode 61
Nick gives us a quick summary of the STAMPEDE study and gives an overview of the latest data.
6 years, 1 month ago
Episode 60: Cora Sternberg discusses AMG 160 - a bispecific antibody in prostate cancer
Season 1 Episode 60
AMG 160; a half-life extended (HLE) bispecific T-cell engager (BITE®) antibody construct is discussed as is the future of immune therapy in CRPC.
6 years, 1 month ago